Patent classifications
A01N37/12
Ionic liquids for transdermal drug delivery
The compositions and methods described herein are topically applied to the skin with negligible or no skin irritation and can direct or prevent transport through the skin. The compositions contain neat ionic liquids, optionally in combination with a drug to be delivered. In a preferred embodiment, the compositions increase transdermal transport of the drug to be delivered. In some embodiments, the compositions disrupt bacterial biofilms. This is particularly beneficial in the treatment of antibiotic resistant skin infections. In other embodiments, the compositions direct delivery within the skin. In still other embodiments, the compositions prevent transfer of substances through the stratum corneum. The disclosed compositions and methods can be tuned and modified such that they can be used to treat or prevent a variety of different diseases and disorders.
Herbicidal compositions including drift retardant agents and methods of making the same
Herbicidal compositions for reducing off-site movement or drift of herbicides are described. The herbicidal compositions can include a drift retardant agent (DRA) along with at least one auxin herbicide and an emulsifying agent, such as an alkylpolysaccharide, a phosphate ester, an alkoxylated castor oil, or a combination thereof. Methods of making such composition are also described.
Herbicidal compositions including drift retardant agents and methods of making the same
Herbicidal compositions for reducing off-site movement or drift of herbicides are described. The herbicidal compositions can include a drift retardant agent (DRA) along with at least one auxin herbicide and an emulsifying agent, such as an alkylpolysaccharide, a phosphate ester, an alkoxylated castor oil, or a combination thereof. Methods of making such composition are also described.
Topical formulations containing mTOR inhibitors
A formulation for topical delivery of mTOR inhibitors with extended shelf-life. The formulation comprises an mTOR inhibitor, a solvent capable of dissolving and stabilizing the inhibitor. The use of the formulation for the treatment of skin lesions and other topical diseases is also disclosed.
Non-sedating dexmedetomidine treatment regimens
Disclosed herein are methods of administering relatively high doses of dexmedetomidine or a pharmaceutically acceptable salt thereof to a human subject, without also inducing significant sedation. The disclosed methods are particularly suitable for the treatment of agitation, especially when associated with neurodegenerative and/or neuropsychiatric diseases such as schizophrenia, bipolar illness such as bipolar disorder or mania, dementia, depression, or delirium.
METHOD FOR PREPARING AND PRESERVING SANITIZED PRODUCTS
Described herein are methods of sanitizing and preserving produce and other agricultural products, for example for consumption as Ready-to-Eat. The methods can comprise treating the products with a sanitizing agent and forming a protective coating over the products.
METHOD FOR PREPARING AND PRESERVING SANITIZED PRODUCTS
Described herein are methods of sanitizing and preserving produce and other agricultural products, for example for consumption as Ready-to-Eat. The methods can comprise treating the products with a sanitizing agent and forming a protective coating over the products.
ANTIMICROBIAL FILTRATION MEMBRANES
A method for in situ production of antimicrobial filtration membranes that uses self-assembly of surfactants such as block copolymers as a template. The mesophase structure (for example hexagonal or lamellar) can be determined, and membrane pore size can be controlled in the nanometer range, by changing the block copolymer and the amounts of the components such as the block copolymer, aqueous solution, monomer, crosslinker, and initiator. The monomer phase cures in the template and there is no need for organic solvents and coagulation bath or other post-modification. As-synthesized membranes were found to have pore sizes with a narrow size distribution in the range of 3-4 nm with a molecular weight cutoff of 1500 g/mol and displayed both excellent fouling resistance and high permeance of water, vastly outperforming a conventional NIPS UF membrane. The monomer can comprise a quaternary ammonium group so that the membrane is antibacterial. The block copolymer can comprise hydrophilic blocks which form the surfaces of the membrane pores, rendering them hydrophilic.
ANTIMICROBIAL FILTRATION MEMBRANES
A method for in situ production of antimicrobial filtration membranes that uses self-assembly of surfactants such as block copolymers as a template. The mesophase structure (for example hexagonal or lamellar) can be determined, and membrane pore size can be controlled in the nanometer range, by changing the block copolymer and the amounts of the components such as the block copolymer, aqueous solution, monomer, crosslinker, and initiator. The monomer phase cures in the template and there is no need for organic solvents and coagulation bath or other post-modification. As-synthesized membranes were found to have pore sizes with a narrow size distribution in the range of 3-4 nm with a molecular weight cutoff of 1500 g/mol and displayed both excellent fouling resistance and high permeance of water, vastly outperforming a conventional NIPS UF membrane. The monomer can comprise a quaternary ammonium group so that the membrane is antibacterial. The block copolymer can comprise hydrophilic blocks which form the surfaces of the membrane pores, rendering them hydrophilic.
Volatile Organic Compound Formulations Having Antimicrobial Activity
The present subject matter includes novel chemical formulations having antimicrobial, antifungal, antiseptic, and related effect in a wide range of applications for treating or preventing infections as well as treating various surfaces that may become tainted with infectants. In some embodiments, the formulation includes isoamyl hexanoates and at least one of propanoic and/or isobutyric acid.